


**Supplementary Figure S1:** Summary of *in vivo* experimental design. A total of 90 male BALB/c mice were used and CRC was induced in 80 animals by azoxymethane (AOM) intraperitoneal injections for two successive (10 mg/Kg/week). Treatments with 5-FU (50 mg/Kg/week), active VD<sub>3</sub> (0.07 µg/Kg/day; five times/week) and/or metformin (430 mg/Kg/day; five times/week) single, dual and triple therapies started at week-21 post AOM injections and lasted for 4 weeks.



**Supplementary Figure S2:** Cells were treated with different concentrations of the drugs of interest for 24h, and the IC<sub>50</sub> for each determined using the MTT cell viability assay.

**Supplementary Table S1.** The sequences of PCR primers used for the detection of human *GAPDH*, *PIK3CA*, *AKT1*, *mTOR*, *PTEN*, *CCND1*, *CCND3*, *CDKN1A*, *CDKN1B*, *BCL2*, *Cytochrome C*, and *Caspase-3* mRNAs in colon samples including the corresponding genes accession numbers and amplicon sizes.

Genes	Forward	Reverse	Amplicon size
<b><i>GAPDH</i></b> (NCBI: NM_002046.5)	5' CAC ATG GCC TCC AAG GAG TAA 3'	5' TGA GGG TCT CTC TCT TCC TCT TGT 3'	74 bp
<b><i>PIK3CA</i></b> (NCBI: NM_006218.4)	5' GGA CCC GAT GCG GTT AGA G 3'	5' ATC AAG TGG ATG CCC CAC AG 3'	168 bp
<b><i>AKT1</i></b> (NCBI: NM_001382431.1)	5' CTC AGT GTC GTC AGA GCC C 3'	5' ATG GAA AGC AGG CCA GAC TC 3'	100 bp
<b><i>mTOR</i></b> (NCBI: NM_004958.4)	5' GAC GAG AGA TCA TCC GCC AG 3'	5' ACA AGG GAC CGC ACC ATA AG 3'	97 bp
<b><i>PTEN</i></b> (NCBI: NM_000314.8)	5' CTC AGC CGT TAC CTG TGT GT 3'	5' AGG TTT CCT CTG GTC CTG GT 3'	129 bp
<b><i>CCND1</i></b> (NCBI: NM_053056.2)	5' TGA CCC CGC ACG ATT TCA TT 3'	5' CAT GGA GGG CGG ATT GGA AA 3'	143 bp
<b><i>CCND3</i></b> (NCBI: NM_001136017.3)	5' GGT GCA ATC CTC TCC TCG C 3'	5' TAG TTC ATG GCC AGG GGG AA 3'	183 bp
<b><i>CDKN1A</i></b> (NCBI NM_000389.4)	5' AGT CAG TTC CTT GTG GAG CC 3'	5' GCA TGG GTT CTG ACG GAC AT 3'	109 bp
<b><i>CDKN1B</i></b> (NCBI: NM_004064.4)	5' CTG GCC TCA GAA GAC GTC AAA 3'	5' AGG ATG TCC ATT CCA TGA AGT CAG 3'	147 bp
<b><i>BCL2</i></b> (NCBI: NM_000633.3)	5' CTT TGA GTT CGG TGG GGT CA 3'	5' GGG CCG TAC AGT TCC ACA AA 3'	162 bp
<b><i>Cytochrome C</i></b> (NCBI: NM_018947.6)	5' CGT TGT GCC AGC GAC TAA AA 3'	5' TGG CAC TGG GAA CAC TTC AT 3'	88 bp
<b><i>BAX</i></b> (NCBI: NM_001291428.1)	5' TCG CCC TTT TCT ACT TTG CCA 3'	5' GTC CTG GAG ACA GGG ACA TCA 3'	195 bp
<b><i>CASP3</i></b> (NCBI: NM_004346.3)	5' CTC TGG TTT TCG GTG GGT GT 3'	5' CCA CTG AGT TTT CAG TGT TCT CC 3'	90 bp

**Supplementary Table S2:** Serum concentrations (mean  $\pm$  SD) of liver enzymes, total protein, albumin, creatinine, and urea in the different study groups.

	<b>NC group</b>	<b>PC group</b>	<b>5-FU group</b>	<b>VD3 group</b>	<b>Met group</b>	<b>VF group</b>	<b>MF group</b>	<b>VMF Group</b>
<b>ALT (IU/L)</b>	58.7 $\pm$ 5.1	61.02 $\pm$ 4.6	63.3 $\pm$ 5.1	57.9 $\pm$ 6.4	58.3 $\pm$ 5.7	57.8 $\pm$ 4.7	59.1 $\pm$ 4.4	60.2 $\pm$ 5.5
<b>AST (IU/L)</b>	51.3 $\pm$ 6.3	53.2 $\pm$ 4.7	56.1 $\pm$ 7.2	52.9 $\pm$ 5.9	52.5 $\pm$ 6.6	54.8 $\pm$ 5.6	52.7 $\pm$ 6.6	51.8 $\pm$ 4.7
<b>ALP (IU/L)</b>	108.1 $\pm$ 12.9	105.2 $\pm$ 10.3	111.4 $\pm$ 17.6	107.9 $\pm$ 11.2	105.8 $\pm$ 10.3	101.5 $\pm$ 13.2	107.8 $\pm$ 9.9	105 $\pm$ 13.3
<b>Total bilirubin (mg/dL)</b>	0.45 $\pm$ 0.2	0.48 $\pm$ 0.3	0.47 $\pm$ 0.3	0.45 $\pm$ 0.3	0.46 $\pm$ 0.1	0.49 $\pm$ 0.3	0.46 $\pm$ 0.1	0.46 $\pm$ 0.09
<b>Total protein (g/dL)</b>	7.5 $\pm$ 0.6	7.4 $\pm$ 0.4	7.1 $\pm$ 0.7	7.6 $\pm$ 0.5	7.2 $\pm$ 0.3	7.4 $\pm$ 0.6	7.8 $\pm$ 0.7	7.5 $\pm$ 0.6
<b>Albumin (g/dL)</b>	4.1 $\pm$ 0.33	3.7 $\pm$ 0.41	4.0 $\pm$ 0.45	4.4 $\pm$ 0.57	4.2 $\pm$ 0.44	3.8 $\pm$ 0.41	4.2 $\pm$ 0.34	4.3 $\pm$ 0.46
<b>Creatinine (mg/dL)</b>	0.47 $\pm$ 0.08	0.51 $\pm$ 0.12	0.48 $\pm$ 0.11	0.48 $\pm$ 0.14	0.53 $\pm$ 0.15	0.46 $\pm$ 0.21	0.53 $\pm$ 0.24	0.50 $\pm$ 0.16
<b>Urea (mg/dL)</b>	41.2 $\pm$ 6.8	41.3 $\pm$ 5.7	43.2 $\pm$ 5.4	43.4 $\pm$ 6.1	40.4 $\pm$ 7.3	42.7 $\pm$ 6.6	40.8 $\pm$ 6.9	43.3 $\pm$ 6.1